D Boral Capital Downgrades CERo Therapeutics (NASDAQ:CERO) to Hold

CERo Therapeutics (NASDAQ:CERO) was downgraded by investment analysts at D Boral Capital from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reissued a “hold” rating on shares of CERo Therapeutics in a report on Tuesday. Maxim Group cut shares of CERo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CERo Therapeutics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $45.00.

CERo Therapeutics Stock Performance

Shares of NASDAQ:CERO opened at $0.06 on Tuesday. CERo Therapeutics has a fifty-two week low of $0.05 and a fifty-two week high of $572.00. The company’s 50-day moving average is $2.92 and its 200 day moving average is $6.97. The company has a market capitalization of $72,300.00, a P/E ratio of 0.00 and a beta of 0.30.

CERo Therapeutics (NASDAQ:CERO) last issued its quarterly earnings results on Friday, August 22nd. The company reported ($61.71) EPS for the quarter, beating analysts’ consensus estimates of ($70.23) by $8.52.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CERo Therapeutics stock. Armistice Capital LLC bought a new stake in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 312,000 shares of the company’s stock, valued at approximately $228,000. Armistice Capital LLC owned approximately 5.80% of CERo Therapeutics at the end of the most recent quarter. 29.64% of the stock is owned by institutional investors and hedge funds.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.